等待开盘 08-20 09:30:00 美东时间
+0.090
+0.56%
Skye Bioscience and Redx Pharma have entered into a definitive transaction agreement to merge, forming Fibrx Therapeutics, a fibrosis-focused company. The combined entity will trade on Nasdaq and is backed by $125 million in financing, aiming to fund operations through 2029. Fibrx’s lead program, RXC008, a GI-restricted pan-ROCK inhibitor for fibrostenotic Crohn’s disease, is set to begin a Phase 2 clinical trial with topline data expected in H2 ...
08-14 13:33
经济观察网 培生(PSO)2026年上半年收入17.79亿英镑,同比增长4%,调整后营业利润同比增长14%,AI嵌入推动效率提升,收购K-12数字课程平台推进生...
08-08 23:15
Mission Produce, a global leader in fresh Hass avocados, will host an Investor Day in New York City on October 8, 2026. The event will focus on the company’s strategic priorities and long-term growth plans following its acquisition of Calavo Growers and the transition of John Pawlowski to CEO. Presentations from senior leadership and a Q&A session will be featured. A live webcast and replay will be available on the company’s investor relations we...
08-07 12:00
Safe Harbor, a fintech platform serving the cannabis industry, has launched a new Multiple Employer 401(k) Plan, attracting six new clients, including a multistate operator. Canopy HR, an HR provider for the cannabis industry, has endorsed the plan, validating its design and compliance framework. The plan addresses the industry's need for accessible retirement benefits, often challenging due to traditional providers' reluctance to serve cannabis ...
08-06 12:00
Immutep Limited provided an update on its activities for Q4 FY26, highlighting progress in its eftilagimod alfa (efti) program and IMP761 development. Pooled analysis of five efti trials showed a 7.7-month median overall survival benefit in biological responders across four tumor types. IMP761, the only LAG-3 agonist antibody in clinical development, met its primary safety endpoint and demonstrated significant pharmacodynamic activity in a first-...
07-30 12:00
Immutep Limited announced that an abstract from its EFTISARC-NEO Phase II trial, evaluating eftilagimod alfa in soft tissue sarcoma patients, has been accepted for presentation at the 2026 ESMO Congress in Madrid. The abstract focuses on health-related quality of life (HRQoL) data from the trial, which combines eftilagimod alfa, pembrolizumab, and radiotherapy. The full abstract will be available on the ESMO website on October 19, 2026, and the p...
07-24 12:00
Pearson ( ($GB:PSON) ) has provided an update. Pearson plc disclosed that Tom a...
07-17 16:22
JP Morgan analyst Daniel Kerven downgrades Pearson (NYSE:PSO) from Overweight to Neutral.
07-14 17:57